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ABSTRACT
The regulation of skeletal muscle gene expression
during myogenesis is mediated by lineage-specific
transcription factors in combination with numerous
cofactors, many of which modify chromatin struc-
ture. However, the involvement of scaffolding
proteins that organize chromatin and chromatin-
associated regulatory proteins has not extensively
been explored in myogenic differentiation. Here,
we report that Scaffold attachment factor b1
(Safb1), primarily associated with transcriptional
repression, functions as a positive regulator of
myogenic differentiation. Knockdown of Safb1
inhibited skeletal muscle marker gene expression
and differentiation in cultured C2C12 myoblasts. In
contrast, over-expression resulted in the premature
expression of critical muscle structural proteins
and formation of enlarged thickened myotubes.
Safb1 co-immunoprecipitated with MyoD and
was co-localized on myogenic promoters. Upon
Safb1 knockdown, the repressive H3K27me3
histone mark and binding of the Polycomb histone
methyltransferase Ezh2 persisted at differentiation-
dependent gene promoters. In contrast, the appear-
ance of histone marks and regulators associated
with myogenic gene activation, such as myogenin
and the SWI/SNF chromatin remodelling enzyme
ATPase, Brg1, was blocked. These results indicate
that the scaffold protein Safb1 contributes to the
activation of skeletal muscle gene expression
during myogenic differentiation by facilitating the
transition of promoter sequences from a repressive
chromatin structure to one that is transcriptionally
permissive.
INTRODUCTION
Skeletal muscle differentiation involves morphological
and transcriptional dynamics that turn a non-
differentiated population of mononucleated myoblasts
into multinucleated striated muscle ﬁbres through a
multistep process regulated by the muscle regulatory
factors (MRFs) MyoD, Myf5, Myf6/MRF4 and
myogenin. MRFs collaborate with sequence-speciﬁc tran-
scription factors such as the myocyte enhancer factor-2
(MEF2) family of activators, chromatin remodelling
enzymes and histone-modifying enzymes to generate tran-
scriptional regulatory networks that promote skeletal
muscle differentiation (1–3). In addition to regulators
that induce and drive differentiation, myogenic genes are
marked prior to the onset of differentiation by the depos-
ition of the variant histone H3.3 (4). Despite the complex-
ity of myogenic gene regulation, there is increasing
evidence that other factors that are not expressed in a
tissue-speciﬁc manner play fundamental roles in the
control of cell differentiation (5–10).
One class of such factors includes nuclear scaffold attach-
ment proteins. SATB1 (special AT-rich sequence-binding
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protein 1) is a well-characterized protein associated with
chromatin and the nuclear matrix (11) that forms a three-
dimensional ‘cage-like’ network structure in mouse thymo-
cyte nuclei (12). In the context of T-cell development,
SATB1 regulates gene activation by folding chromatin
into loop domains, tethering specialized DNA elements to
a SATB1 network structure containing chromatin
remodelling enzymes and speciﬁc transcription factors to
the anchor sites and thereby regulating the status of
histone modiﬁcation and nucleosomal positioning over
long distances of DNA (13,14). More recently, the
scaffold attachment factor A (SAF-A) has been identiﬁed
as a factor required for the recruitment of Xist RNA on the
inactive X chromosome and the concomitant increase of
the repressive histone mark H3K27me3 through a mechan-
ism that involves the RNA- and DNA-binding properties
of SAF-A (15).
Scaffold attachment factor b1 (Safb1) is a large multi-
functional protein that participates in a variety of cellular
processes. It is involved in higher order chromatin struc-
ture and in the partitioning of chromatin into distinct
topologically independent loops (16,17). Safb1 contains
different functional domains; it binds RNA via its
central recognition RNA motif domain (18,19) and has
been isolated in complexes with RNA-processing
proteins and RNA pol II. Thus, it has been suggested to
be part of a ‘transcriptosome’ complex. Safb1 also
contains a nuclear localization domain a Glu/Arg, Ser/
Lys and Gly-rich domain that mediates protein–protein
interactions, and a SAF-Box, which is a homeodomain-
like DNA-binding motif that interacts with AT-rich
scaffold/matrix attachment regions (S/MARs) (20,21).
Transcriptional repression seems to be the most promin-
ent function of Safb1. Safb1 was initially reported to
repress estrogen-dependent transcription, but recent
studies suggest that it may function in a more widespread
manner by mediating repression of immune regulators and
apoptotic genes (22,23).
Here, we show that Safb1 is able to interact with
MyoD to co-occupy skeletal muscle promoter regions
before and during the course of C2C12 cell differentiation.
Reduced levels of Safb1 led to inhibition of cell differenti-
ation, with a concomitant reduction of myogenic marker
gene expression. In addition, the changes in the local chro-
matin environment that are expected during differenti-
ation did not occur. Reduction of Safb1 resulted in
maintenance of a repressive chromatin structure at
target promoters, including continued association with
the Polycomb group protein Ezh2 and its associated
histone modiﬁcation H3K27me3. Binding of proteins
associated with myogenic gene activation, including
myogenin, the SWI/SNF chromatin remodelling
enzyme ATPase, Brg1, and incorporation of acetylated
H3Ac and H4Ac at promoters in cells induced to
differentiate in the absence of Safb1 did not occur.
Thus, we propose a novel role for Safb1 as a scaffold
protein that facilitates the transition from a repressive
chromatin environment to an active and transcriptionally
permissive chromatin environment during myogenic
differentiation.
MATERIALS AND METHODS
Tissue culture, plasmids and viral constructs
Mouse C2C12 myoblasts (ATCC collection 1772) were
maintained in growth media (GM) composed of
Dulbecco’s modiﬁed Eagle’s medium (Gibco) supple-
mented with 10% fetal bovine serum, 100U/ml penicillin,
100mg/ml streptomycin and 2mM glutamine (Gibco).
Differentiation was induced once cells reached 80% con-
ﬂuence with media supplemented with 2% horse serum
(Gibco) instead of 10% fetal bovine serum. C2C12 cells
transduced with lentiviral particles expressing shRNAs
against mouse Safb1 or non-speciﬁc sequences were
grown and differentiated in presence of 2.5mg/ml of puro-
mycin (Invitrogen). Cells transduced with retroviral
vectors expressing the human cDNA of SAFB1 were
selected with 700mg/ml of G418 (Gibco). Lentiviral
packaging 293T and BOSC cells were grown in
Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% fetal bovine serum and antibiotics.
Retroviruses expressing human SAFB1 were generated
by transient transfection of BOSC cells with pBABE or
pBabe-SAFB1, which was generated by subcloning the
SAFB1 cDNA from pcDNA1-SAFB1 (24) using EcoRI
and cloned into the EcoRI site of the pBABE vector.
Forty-eight hours post-transfection, the supernatant con-
taining viral particles was collected and used to transduce
C2C12 cells. Lentiviruses expressing shRNA against Safb1
and control sequences were generated by transfecting
pLenti-Safb1-1, pLenti-Safb1-2 and pLenti-Scrambled
vectors in 293T cells. After 48 h of transfection, super-
natants containing lentiviral particles were collected,
used to transduce C2C12 cells and selected with 2.5mg/
ml of puromycin. Oligonucleotides used to generate
shRNA-Safb1-1 were as follows: 50-GATCCGGACATC
AGTGTGCTGGATGAGTGTGCTGTCCTCATCCAG
CACACTGATGTCCTTTTTGGAAA-3, and sh-RNA
Safb1-2: 50-GATCCGCTGCAGGAGCATGCTATAGA
GTGTGCTGTCCTCTATAGCATGCTCCTGCAGCT
TTTTGGAAA-30.
RNA isolation and gene expression analysis
Total RNA was isolated from samples using TRIzol
reagent (Invitrogen) according to the manufacturer’s in-
structions. One microgram of total RNA from each
sample was used to prepare cDNA using Superscript III
reverse transcriptase (Invitrogen). Quantitative RT-PCR
was performed by monitoring in real time the increase in
ﬂuorescence of the SYBR Green dye using the Fast SYBR
green master mix on the ABI StepOne Plus Sequence
Detection System (Applied Biosystems). Relative expres-
sion levels for each gene were determined using the
Comparative Ct method (25) and normalized to the
relative levels of EF1-alpha expression (26). One-tailed t
tests were used for statistical analyses. Primer sequences
used for real time PCR are as follows:
EF1alpha For: 50-AGCTTCTCTGACTACCCTCCAC
TT-30, Rev: 50-GACCGTTCTTCCACCACTGATT-30;
Myogenin For: 50-CAAGTGTGCACATCTGTTCTAG
TCTCT-30, Rev: 50-GTATCATCAGCACAGGAGACC
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TTGGT-30; Skeletal Actin For: 50-TTGTGCGCGACAT
CAAAGAGAAGC-30, Rev: 50- GAAACGCTCATTGCC
GATGGTGAT-30; MyhIIb For: 50- TCAATGAGATGG
AGATCCAGCTGAAC-30, Rev: 50-GTCCAGGTGCAG
CTGTGTGTCCTTC-30; MCK For: 50-GCCGGGGATG
AGGAGTCCTAC-30, Rev: 50-GCAGTGCGGAGGCA
GAGTGTA-30; Alpha Sarcoglycan For: 50-AGAGGCT
GCTGCTGCTGATT-30, Rev: 50-GAGGTGCCAAGGT
GTCATAG-30; Safb1 For: 50-GAAGAAGCGGAACCT
CGACTC-30, Rev: 50-TCATCAGGATTCCCACCTTC
A-30; Dystrophin For: 50-GTTCATTGATGGAGACGG
AA-30, Rev: 50-GCACTTCAGCTTCTTCATCT-30.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays using
cultured C2C12 cells and E9.5 dpc mouse embryos were
performed as previously described (27,28). Brieﬂy, cells,
somite-enriched tissue or yolk sac were ﬁxed with 1% for-
maldehyde to cross-link proteinDNA complexes and
then lysed in a buffer containing 1% SDS, 10mM
EDTA, pH 8, and 50mM Tris-HCl, pH 8, with protease
inhibitors. After sonication, chromatin was pre-cleared for
1 h with protein A-agarose beads blocked with DNA
salmon sperm, and lysates were incubated overnight
with speciﬁc antibodies against Safb1 (A300-812A,
Bethyl), MyoD (Santa Cruz Biotechnology, sc-304),
Myogenin (Santa Cruz Biotechnology, sc-576),
H3K27me3 (Millipore, 07-449), Ezh2 (Millipore,
05-1319), H4Ac (Millipore, 06-866), H3Ac (Millipore,
06-599), polyclonal rabbit antisera against Brg1 (29) or
normal rabbit IgG (Santa Cruz Biotechnology, sc-3888).
Cross-linking was reversed, and DNA was puriﬁed using
MiniElute Spin Columns (QIAGEN, Hilden, Germany)
and used as template for quantitative PCR using the
Fast SYBR green master mix on the ABI StepOne Plus
Sequence Detection System. Quantiﬁcation was per-
formed using the comparative Ct method and presented
as fold differences relative to input and values obtained by
normal rabbit IgG with the formula (2[(Ct IgG-Ct
input)(Ct Ab-Ct input)]) (25). Re-ChIP, or sequential ChIP,
experiments were performed as described (30). Two-tailed
t tests were used for statistical analyses. Primer sequences
used for real time PCR were as follows: Myogenin pro-
moter (10 to 150), For: 50-ACGCCAACTGCTGGGT
GCCA-30
Rev 50-GAATCACATGTAATCCACTGGA-30; MCK
enhancer (1050 to 1210), For: 50-GACACCCGAGAT
GCCTGGTT-30, Rev: 50-GATCCACCAGGGACAGGG
TT-30; Skeletal Actin promoter (81 to 265), For: 50-AC
CAGCGGTCAAAGCAGTG-30, Rev: 50-CTCCCAACT
GGCTCCAAGG-30; MyhIIb promoter (20 to 155),
For: 50-CACCCAAGCCGGGAGAAACAGCC-30, Rev:
50-GAGGAAGGACAGGACAGAGGCACC-30;
IgH enhancer (11–158 of enhancer core sequence)
For: 50-GCCGATCAGAACCAGAACACC-30, Rev:
50-TGGTGGGGCTGGACAGAGTGTTTC-30.
Co-immunoprecipitation and western blots
Protein extracts from myoblasts and myotubes were
obtained with RIPA modiﬁed buffer (50mM Tris HCl
pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 0.25%
sodium deoxycholate, supplemented with proteases inhibi-
tors). For IPs, extracts were pre-cleared for 1 h with
protein A (GE) at 4C. Four milligrams of speciﬁc
antibodies or rabbit or mouse control IgG were added
to the extracts and incubated overnight at 4C with
rotation. Immunocomplexes were collected by adding
protein A, and after extensively washing, 40ml of
loading buffer was added and the samples were boiled to
elute the complexes.
Antibodies used for western blots were anti-Safb1
(Bethyl A300-812A), anti-Myogenin (BD-556358), anti-
MHC (Hybridoma MF-20; Developmental Studies
Hybridoma Bank, Dept. Biology, University of Iowa),
anti-MyoD (Santa Cruz Biotechnology, sc-32758 and
sc-304), anti-PI3K (Millipore 06-496), polyclonal rabbit
antisera against Brg1 (29) and anti-b-actin (Santa Cruz
Biotechnology, sc-81178). Where indicated, western blots
were quantiﬁed using ImageJ software.
Immunoﬂuorescence
C2C12 cells were grown on coverslips treated with
collagen type I (Sigma) in 24-well plates. Cells were ﬁxed
in methanol at 70C for 10min, blocked with 10% fetal
bovine serum, 10% albumin and 1% TBS Tween and
permeabilized with 0.05% Triton X-100. Subsequently,
cells were incubated overnight at 4C with anti-MHC
primary antibody (Hybridoma MF-20; Developmental
Studies Hybridoma Bank, Dept. Biology, University of
Iowa). After three washes with phosphate-buffered
saline, samples were incubated with secondary antibodies
coupled with ﬂuorescein isothiocyanate or carboxymethyl
indocyanine-3 for 1 h at room temperature. Samples were
washed and mounted in Vectashield–40,6-diamidino-2-
phenylindole medium (Vector Laboratories). Immu-
nostaining analysis was recorded using an Epiﬂuorescence
Zeiss Axioplan 2 microscope (Zeiss MicroImaging 9, Inc.
New York, NY).
RESULTS
Safb1 is present in a myogenic protein complex
containing MyoD
Studies of the human xanthine oxidoreductase gene have
previously shown that E boxes upstream of the transcrip-
tion start site negatively regulate gene expression and that
these sequences bind a complex of regulatory factors that
includes Safb1, another scaffold protein, SAF-A, and
transcriptional and chromatin regulatory proteins.
Because the activation of myogenic genes requires E
boxes that bind to the MyoD family of myogenic regula-
tory proteins, we hypothesized that myogenic gene activa-
tion might involve cooperation between MyoD and
related factors and the Safb1 scaffold protein. First, we
analysed the temporal expression pattern of Safb1 during
a time course of differentiation in C2C12 myoblasts by
real-time PCR and western blot analyses. Safb1 mRNA
levels were elevated 1.5- to 2-fold in conﬂuent and in
differentiating C2C12 cells (Figure 1A); however, we
observed no signiﬁcant changes in Safb1 protein
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abundance as a consequence of cell differentiation
(Figure 1B). Co-immunoprecipitation assays were
performed using protein extracts from C2C12 cells to
determine whether Safb1 could interact with MyoD. As
shown in Figure 1C, association between endogenous
Safb1 and endogenous MyoD was revealed when an
anti-Safb1 antibody was used to immunoprecipitate
protein extracts from both proliferating myoblasts (GM)
and differentiated myotubes (DM). Additionally, the anti-
MyoD antibody was able to immunoprecipitate Safb1 in
extracts from both stages of differentiation (Figure 1C).
These data suggest a role of Safb1 as a potential cofactor
of MyoD during transcriptional regulation of skeletal
muscle genes.
Safb1 is required for C2C12 cell differentiation and
skeletal muscle gene expression
To better understand the function of Safb1 during skeletal
myogenesis, we conducted knockdown experiments by
transducing C2C12 cells with a lentivirus expressing
speciﬁc shRNA against the mouse Safb1 gene or a
scrambled sequence. First, we performed proliferation
assays and determined that Safb1 knockdown cells
proliferated at the same rate as the control cells
(Figure 2A), suggesting that Safb1 deﬁciency did not
affect the progression of myoblasts through the cell
cycle. A western blot analysis conﬁrmed knockdown of
Safb1 in the proliferating myoblasts (Figure 2A). We
next examined the effect of reduction of Safb1 protein
levels on myoblast differentiation; Figure 2B shows the
extent of Safb1 knockdown in cells differentiated for
72 h. Additional western blot analysis to examine the
expression of the skeletal muscle differentiation marker,
Myosin Heavy Chain (MHC), revealed a signiﬁcant block
in the accumulation of MHC proteins compared with the
expression of MHC in control cells expressing the
scrambled sequence shRNA (Figure 2B). Furthermore,
formation of myotubes in knockdown C2C12 cells was
markedly reduced and was accompanied by reduction in
the number of MHC-positive myotubes (Figure 2C) as
shown by immunostaining experiments. Total RNA
from knockdown cells was extracted to analyse gene
expression of muscle-speciﬁc genes that are up-regulated
as function of muscle differentiation. As shown in
Figure 2D, expression of myogenin was modestly
affected by expression of the shRNAs targeting Safb1
compared to the scrambled sequence control. However,
transcription levels of muscle creatine kinase, myosin
heavy chain IIb, skeletal actin, dystrophin and alpha-
sarcoglycan, genes normally up-regulated at later times
in differentiating myotubes, were markedly reduced in
the knockdown cells. These results suggest an important
role of Safb1 during transcriptional activation of skeletal
muscle genes during myogenesis.
In contrast, over-expression of SAFB1 in wild-type
C2C12 cells induced formation of enlarged thicker
myotubes after 72 h of differentiation (Figure 3A).
Interestingly, the presence of MHC was detected
Figure 1. Safb1 co-immunoprecipitates with MyoD and Brg1 during C2C12 cell differentiation. (A and B) Total RNA and protein from
proliferating myoblasts in growth media (GM), conﬂuent myoblasts (time 0) and myoblasts exposed to differentiation media (DM) for up to
72 h were collected and analysed for Safb1 mRNA and protein levels. Myogenic markers of differentiation Myogenin and MCK were monitored
as controls for C2C12 cell differentiation. b-actin was monitored as a loading control for the western blot. mRNA data are presented as the
expression relative to EF-1a levels. The expression in growth media was normalized to 1. Data represent the average of three independent
analyses±SEM. t-test analysis of Safb1 mRNA levels indicated that only the 0 h timepoint gave a P value> 0.05 relative to the value obtained
in proliferating myoblasts. ImageJ quantiﬁcation of the western blot indicated that Safb1 levels varied by no more than 15% from the level present in
growth media through 48 h post-differentiation and that Safb1 levels were reduced by 40% in differentiated cells (72 h post-differentiation). (C)
Whole cell protein extracts from myoblast and myotubes were collected to perform co-immunoprecipitation assays for Safb1 and MyoD. Asterisks
indicate the MyoD or Safb1 speciﬁc bands. GM, growth media; DM, differentiation media; IP, immunoprecipitation; WB, western blot.
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prematurely at 48 h post-differentiation in SAFB1
over-expressing cells (Figure 3B), even though MHC
protein levels did not achieve the same level of induction
as observed in control cells at 72 h. The reason for the lack
of full MHC induction in these cells was not established.
We further explored the speciﬁcity of our results by
asking whether introduction of the SAFB1-expressing
vector would rescue the block to MHC expression and
differentiation caused by shRNA-mediated Safb1
knockdown. Expression of SAFB1 in control cells express-
ing the control shRNA resulted in enlarged myotubes
(Figure 3C, middle panel), in agreement with the results
obtained when SAFB1 was introduced into parental
C2C12 cells (Figure 3A). Introduction of SAFB1 in cells
expressing the shRNA against Safb1 rescued the expres-
sion of MHC and the formation of myotubes (Figure 3C,
bottom panel), although the myotubes that formed were
enlarged and thicker than myotubes that formed in the
parental and control C2C12 cells. Consistent with this
observation, Safb1 knockdown cells expressing SAFB1
showed both rescue of Safb1 expression as well as prema-
ture MHC expression (Figure 3D), as was observed in
SAFB1-expressing parental and control shRNA-express-
ing cells. These experiments further support the conclu-
sion that Safb1 is a positive regulator of myogenesis.
Safb1 is present at myogenic regulatory regions
Having observed the endogenous interaction of Safb1 and
MyoD and considering the previous reports describing the
ability of Safb1 to interact with chromatin (23,31), we
reasoned that Safb1 could be playing a direct role in tran-
scriptional regulation of skeletal muscle genes during
myogenesis. To test this hypothesis, we performed ChIP
assays before and during differentiation of C2C12 cells.
As shown in Figure 4A, Safb1 was able to bind to skeletal
muscle gene regulatory sequences both in proliferating
myoblasts as well as in differentiated myotubes
(Figure 4A). As expected, binding of MyoD was found
in muscle promoters both in proliferating myoblasts and
in myotubes, with a signiﬁcant enhancement of MyoD
binding at the MCK gene (32). In contrast, myogenin
protein was inducibly recruited to muscle regulatory
regions upon cell differentiation, in agreement with prior
studies (33–35). The IgH enhancer was used as a negative
Figure 2. Safb1 knockdown blocks C2C12 cell differentiation and inhibits skeletal muscle genes expression. (A) shRNA-mediated knockdown of
Safb1 in proliferating myoblasts does not affect proliferation. Two different sequences against Safb1 mRNA (sh1 and sh2) were used. Knockdown of
Safb1 in proliferating myoblasts was conﬁrmed by western blot. PI3K levels were monitored as a loading control. Cell counts were taken at 24 h
intervals after seeding of equal numbers of cells. Data represent the average of three independent analyses±SEM. sh control cells (sh ctrl) express a
scrambled sequence shRNA. (B) Conﬁrmation of Safb1 knockdown in cells induced to differentiate for 72 h compared with cells expressing the
control shRNA. MHC protein levels were also reduced in differentiated Safb1 knockdown cells. b-actin levels were monitored as a loading control.
(C) Immunostaining indicates that the population of MHC-positive myotubes is markedly reduced in Safb1 knockdown C2C12 cells induced to
differentiate. Nuclei were counterstained with DAPI. (D) Total RNA from C2C12 cells expressing shRNA against Safb1 was used to analyse
expression levels of Myogenin, Muscle Creatine Kinase Myosin heavy chain IIb (Myh IIb), Skeletal Actin, Dystrophin and Alpha Sarcoglycan
(alpha-SG) genes. Expression in differentiated sh-control (ctrl) cells was normalized to 1. Quantiﬁcation represents the average of three independent
experiments±SEM t test analysis indicates that all values for mRNA levels in the differentiated knockdown cells are signiﬁcantly reduced compared
with the mRNA levels in control differentiated cells (P< 0.05 for Sh2 KD of myogenin, P< 0.01 for all other data points).
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sequence control because it contains a consensus E box
but does not bind to myogenic transcription factors in
myoblasts or in differentiated cells (4,26,34,36–40).
To conﬁrm the physiological relevance of this observation,
we looked for the presence of Safb1 at muscle promoters
in the context of mouse embryonic development.
Mouse embryos at 9.5 dpc were dissected, and tissue
enriched in somites was used to perform ChIP analysis
following the methodology previously described (27).
As shown in Figure 4B, both Safb1 and MyoD were
enriched at the myogenin, muscle creatine kinase,
skeletal actin and myosin heavy chain IIb regulatory se-
quences in tissue enriched in somites. Neither Safb1 nor
MyoD was present at these myogenic promoters in
yolk sac, the tissue used as negative control. These data
suggest a role for Safb1 as a cofactor that directly
participates in the transcriptional machinery present at
skeletal muscle loci during activation of skeletal muscle
genes.
The co-IP and ChIP data suggest that Safb1 and MyoD
may co-occupy myogenic regulatory regions both before
and after induction of differentiation. To address this
question, sequential chromatin immunoprecipitation
(ChIP-ReChIP) experiments were performed. ChIP-
ReChIP revealed that MyoD is recruited to regulatory
sequences of the myogenin, muscle creatine kinase and
Figure 3. Over-expression of SAFB1 leads to formation of enlarged, thicker, MHC-positive myotubes. (A) C2C12 cells infected with the shRNA
control vector, an shRNA against Safb1 or a vector encoding SAFB1 were immunostained for MHC after 48 and 72 h of differentiation. Nuclei were
counterstained with DAPI. (B) Western blot of protein extracts obtained from duplicate plates of cells in (A) showing Safb1 and MHC levels. PI3K
levels were monitored as a loading control. (C) Immunostaining indicates that exogenous expression of SAFB1 in Safb1 knockdown cells rescues
MHC expression and results in myotube formation similar to that observed in sh-control cells over-expressing SAFB1. Nuclei were counterstained
with DAPI. (D) Rescue of Safb1 expression after knockdown of endogenous Safb1 (shSafb1+SAFB1), reestablishes MHC expression at 48 h of
differentiation. HA signal indicates the presence of exogenous SAFB1, which is HA-tagged. PI3K levels were monitored as a loading control.
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skeletal actin genes when we used chromatin previously
precipitated with an antibody against Safb1 both in
myoblasts and differentiated cells (Figure 5). Similarly,
when MyoD was used as the ﬁrst target for the
immunoprecipitation, we were able to detect enrichment
of Safb1 at the same sequences. Neither Safb1 nor MyoD
was able to immunoprecipitate myogenic regulatory
sequences after pull down with control anti-IgG. These
data demonstrate that Safb1 and MyoD co-occupy the
same sequences of myogenic genes before differentiation
and that this binding is sustained after the onset of the
cellular differentiation process.
Knockdown of Safb1 favours maintenance of
Polycomb-mediated repressive marks at the regulatory
sequences of myogenic genes and prevents the transition to
an activated chromatin state
We analysed the chromatin environment at myogenic
promoters in myoblasts where Safb1 expression was
Figure 4. Safb1 is recruited to regulatory sequences of skeletal muscle-speciﬁc genes before and during C2C12 cell differentiation and in somite-
enriched tissue isolated from mouse embryos at E9.5. (A) ChIP analysis of skeletal muscle promoters Myogenin, Muscle Creatine Kinase, Myosin
heavy chain IIb (Myh IIb) and IgH (as a negative control) in C2C12 myoblasts (GM) and myotubes differentiated for 72 h (DM). (B) ChIP analysis
of skeletal muscle promoters in somite-enriched tissue obtained from mouse embryos at E9.5 dpc. Yolk sac (YS) from E9.5 embryos was used as
negative control. Quantiﬁcation represents the mean of three independent experiments±SEM. t test analyses indicate that all binding events except
for myogenin binding to myogenic gene promoters in growth media conditions are statistically signiﬁcant (P< 0.05) compared with the IgG controls
(panel A) and that all MyoD and Safb1 binding in E9.5 somite-enriched tissue is statistically signiﬁcant (P< 0.01) compared with binding in yolk sac
(panel B).
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inhibited. As shown in Figure 6A, the knockdown of
Safb1 resulted in minimal or no reduction in the recruit-
ment of MyoD at skeletal muscle gene promoters, whereas
recruitment of Safb1 was compromised, as expected. This
result indicates that Safb1 is not required for the initial
interaction of MyoD with target promoters in myoblasts
and likely functions downstream of MyoD binding to
myogenic loci. Because cells deﬁcient for Safb1 exhibited
reduced differentiation capability, we decided to analyse
the recruitment of known transcriptional repressors and
activators of skeletal muscle genes at muscle promoters
before and after differentiation. The Polycomb group
protein Ezh2 is responsible for tri-methylation of histone
H3 lysine 27 (H3K27me3), a chromatin mark associated
with repressed chromatin (41), and has been shown to
maintain skeletal muscle genes in a repressed state prior
to differentiation (42–44). As shown in Figure 6B, in
control cells, both Ezh2 and H3K27me3 are present at
target gene promoters in myoblasts but are not localized
to these sequences in differentiated control cells.
Knockdown of Safb1 results in roughly equivalent recruit-
ment of the Ezh2 and H3K27me3 to myogenic promoters
in myoblasts and in differentiated cells (Figure 6B). The
data indicate that when Safb1 levels are reduced, the chro-
matin environment associated with Pc Group-mediated
gene repression is maintained despite the onset of differ-
entiation. These data are also consistent with the reduced
transcriptional levels of these genes and the block of cell
differentiation observed upon Safb1 knockdown
(Figure 2C and D).
To further support the idea that myogenic target genes
are maintained in a repressive chromatin environment
when Safb1 levels were reduced, we performed additional
ChIP experiments to examine the recruitment of factors
and histone marks associated with transcriptionally active
myogenic genes. Recruitment of the myogenic activator
myogenin and the SWI/SNF ATPase Brg1, which is
required for chromatin remodelling associated with
myogenic gene activation (26,38,45,46), is normally
enhanced upon differentiation but is compromised in
Safb1 knockdown cells induced to differentiate
(Figure 7). Similar results were observed for the incorpor-
ation of acetylated histones H3 and H4 (Figure 7), which
are histone marks linked to myogenic gene activation as
well as gene activation in general (47,48). These results are
also entirely consistent with the observed inhibition of
myogenic gene expression upon Safb1 knockdown
(Figure 2C and D). We conclude that Safb1 is necessary
to mediate the transition between the repressed chromatin
and transcriptionally competent chromatin at myogenic
promoters during myogenesis.
DISCUSSION
In this work, we showed that Safb1 is a component of the
transcriptional machinery that is required for proper
Figure 5. Safb1 and MyoD are co-localized at regulatory sequences of myogenic promoters in myoblasts prior to the activation of transcription.
ReChIPs were performed by immunoprecipitating chromatin with an antibody against MyoD followed by a second immunoprecipitation using
antibody against Safb1 (upper panel) or using Safb1 as the ﬁrst immunoprecipitating antibody (lower panel) in undifferentiated myoblasts (GM) and
72 h differentiated myotubes (DM). ChIP values were normalized against the input and expressed as relative enrichment of the material precipitated
by the indicated antibody. Data represent the mean of three independent experiments±SEM. t test analyses indicate there is no statistical difference
when comparing MyoD/Safb1 ReChIP signals in growth media with the signals obtained in differentiation media. MyoD/Safb1 ReChIP signals
relative to IgG controls were statistically signiﬁcant (P< 0.05).
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Figure 6. shRNA-mediated knockdown of Safb1 does not alter MyoD recruitment to myogenic sequences but increases Polycomb repressive marks.
Proliferating (GM) or 72 h differentiated (DM) C2C12 cells expressing control shRNA or shRNA against Safb1 were ﬁxed and processed for ChIP
assays using (A) antibodies against MyoD and Safb1 (top panel) or (B) antibodies against Ezh2 and H3K27me3 at the indicated gene regulatory
sequences. H3K27me3 enrichment is presented on the right-hand y-axis in the bottom panel. Data represent the mean of three independent
experiments±SEM. t test analyses indicate that when comparing binding in sh-Safb1-treated differentiated cells with sh-Control differentiated
cells, the binding of Safb1 was signiﬁcantly reduced (P< 0.01), the binding of MyoD was not signiﬁcantly reduced, except for the binding to the
MyhIIb promoter (P=0.045), and the binding of Ezh2 and H3K27me3 were signiﬁcantly reduced (P< 0.01 and P< 0.005, respectively).
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expression of skeletal muscle genes during myogenesis.
Together with MyoD, Safb1 binds to muscle regulatory
sequences both in non-differentiated myoblasts and in
differentiated myotubes, facilitating the transition from a
repressive transcriptional state to an active chromatin
environment to promote myogenic gene expression and
formation of multinucleated myotubes in culture.
Experiments that revealed an association between Safb1
and MyoD in myoblast extracts and that indicated
co-occupancy of myogenic promoter sequences by these
proteins prior to differentiation suggest a mechanism by
which Safb1 could be localized to myogenic gene regula-
tory sequences. The observation that MyoD binding to
myogenic genes in myoblasts was unaffected by Safb1
knockdown supports the idea that MyoD targets Safb1
to differentiation-dependent gene promoters. Such target-
ing could be the result of direct physical interactions
between MyoD and Safb1 or could be mediated by
Figure 7. Recruitment of transcriptional activators and associated chromatin marks is inhibited in Safb1 knockdown cells. Proliferating (GM) or
72 h differentiated (DM) C2C12 cells expressing control shRNA or shRNA against Safb1 were ﬁxed and processed for ChIP assays using antibodies
against Myogenin, Brg1, acetylated H3 or acetylated H4 at the indicated gene regulatory sequences. Data represent the mean of three independent
experiments±SEM. t test analyses indicate that binding of myogenin and Brg1 and incorporation of acetylated H3 and H4 was signiﬁcantly reduced
in differentiated sh-Safb1-treated cells compared with binding/incorporation in differentiated sh-Control cells (myogenin P< 0.05, Brg1 P< 0.002,
acetylated H3 P< 0.005, acetylated H4 P< 0.002).
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other proteins that are known to be present with MyoD,
such as E proteins and Mef2 factors. To date, none of the
experiments that we have performed using bacterially
expressed or in vitro translated proteins support the
hypothesis that MyoD and Safb1 directly interact (unpub-
lished), but the technical limitations of such approaches
do not exclude the possibility that direct interactions occur
but are dependent on post-translation modiﬁcations to
one or both proteins. Our data also indicate that initial
MyoD binding to myogenic genes prior to differentiation
is independent of Safb1. This ﬁnding is consistent with the
idea that MyoD binding in myoblasts is a critical step in
reprogramming the myoblast genome in preparation for
differentiation (32). Based on the data, we predict that
MyoD, or perhaps either MyoD or the related myogenic
regulator Myf5, is required for Safb1 binding. Deﬁnitive
demonstration of this prediction will require assessment of
Safb1 binding to myogenic promoters in myoblasts where
MyoD and /or Myf5 levels have been reduced.
Nuclear scaffold proteins facilitate protein–protein
interactions as well as provide an additional mechanism
for linking to chromatin by binding to AT-rich S/MARs
in the genome (49–51). Thus, Safb1 may function in part
to physically link MyoD-bound myogenic regulatory
sequences to chromatin domains associated with gene
repression or activation. Safb1 has been conﬁrmed as a
nuclear matrix protein (20), and its ability to link to the
nuclear matrix may facilitate gene regulation, as has been
indicated for many other nuclear matrix proteins.
Furthermore, Safb1 has been implicated in organization
of chromatin via its physical interaction with known ATP-
dependent chromatin remodelling proteins such as Chd1
and Brg1 (31,52). Altogether, the involvement of Safb1 in
the regulation of myogenic gene expression emphasizes the
relevance of the local chromatin structure and raises the
provocative possibility that higher order chromatin organ-
ization may also be involved (16,17).
The ChIP data presented in Figures 6 and 7 identify
Safb1 as being necessary for myogenic promoters to
transition from a repressed chromatin state to a
transcriptionally active state. Reduced levels of Safb1
resulted in the maintenance of the Polycomb group
histone methyltransferase Ezh2 and its repressive mark
H3K27me3 on muscle promoters despite induction of
cell differentiation. Ezh2 is a critical negative regulator
of skeletal muscle differentiation (53), and recent work
details how both the Ezh1 paralog protein as well as the
UTX lysine demethylase contribute to myogenic gene ac-
tivation by countering the repressive effects of Ezh2 and
H3K27me3 (54–56). In the absence of removal of Ezh2
and H3K27me3 from myogenic gene promoters, the
normal recruitment of activators, co-activators and
modiﬁed histones associated with transcriptional activa-
tion did not occur. Determining whether Safb1 interacts
directly with Ezh2 or other members of the PRC2 complex
as a mechanism that helps target the enzyme to myogenic
promoters prior to differentiation would be a future step
in better understanding the potential inter-related func-
tions of Ezh2 and Safb1. Similarly, a survey of
Safb1-interacting proteins subsequent to differentiation
signalling may yield insight into the organization of co-ac-
tivators that promote myogenic gene expression.
Exactly how Safb1 functions both pre- and post-differ-
entiation remains to be determined. One possibility is that
Safb1 serves as a scaffold for negative co-regulatory
proteins prior to differentiation, and differentiation-
induced expression of myogenin and/or induction or acti-
vation of other positively acting co-regulatory proteins
displace the negative co-regulatory proteins and use
Safb1 as a scaffold to help associate with target gene
promoters. In this model, Safb1 could act as a co-repres-
sor and a co-activator but would not necessarily change
structurally when differentiation is induced. Other co-
regulatory proteins have also been shown to affect cell
differentiation both positively and negatively. For
example, SWI/SNF chromatin remodelling enzymes are
required for the differentiation of most tissue types
(57,58) yet are reported to act as negative regulators of
transcription at speciﬁc stages of some tissue differenti-
ation events (59) and during ES cell differentiation
(60–62). The arginine methyltransferase Prmt5, like
Safb1, was initially characterized as a negative regulator
of gene expression yet was subsequently shown to be
required for both myogenic- and adipogenic-speciﬁc
gene expression and differentiation (28,63,64). The func-
tional activity of each of these regulators is likely the same
regardless of context; positive or negative outcomes with
regard to transcriptional regulation are almost certainly
dependent on the local chromatin environment in which
the regulator functions.
Another possibility is that Safb1 is structurally modiﬁed
upon differentiation signalling, which may make Safb1
more likely to interact with different transcriptional co-
activators. It has been recently shown that sumoylation
of Safb1 lysines 231 and 294 by the SUMO E3 ligase
PIAS1, modulates the repressor activity of Safb1 by
increasing its ability to interact with HDAC3 in vitro
(24). Because HDAC1 and HDAC2 are known to
interact with MyoD at muscle gene promoters in the
non-differentiated state to repress the transactivation po-
tential of MyoD (26,65,66), it may be possible that the
presence or absence of sumo groups contributes to the
function of Safb1 in myogenesis. However, attempts to
date to identify sumoylated Safb1 in C2C12 myoblasts
or myotubes have not been successful (unpublished
data). Similarly, it has been demonstrated that phosphor-
ylation of Safb1 modulates Safb1 repressor activity at the
hXOR promoter (31). Other as yet uncharacterized post-
translational modiﬁcations could also contribute to Safb1
function during myogenesis.
In conclusion, our work demonstrates that Safb1
scaffold protein can function as a co-activator in a
cellular differentiation process. The evidence suggests
that Safb1 is targeted to myogenic gene regulatory se-
quences by MyoD prior to differentiation and that its
presence facilitates the transition of myogenic gene regu-
latory sequences from a repressed chromatin environment
to an active chromatin environment. Thus, the Safb1
scaffold protein represents a novel type of co-activator
that facilitates the activation of myogenic genes during
myogenic differentiation.
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